Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and neurodegenerative disease researchSEATTLE, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering single-molecule proteome analysis, today announced the launch of an Early Access Program for its novel proteomics platform, with a tau proteoforms assay as i ...